Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 16, 2006 - Issue 9
Submit an article Journal homepage
61
Views
7
CrossRef citations to date
0
Altmetric
Patent Evaluation

Dual-acting β2 agonists/muscarinic antagonists

WO2006023457

Peter Norman Norman Consulting, 18 Pink Lane, Burnham, Buckinghamshire, SL1 8JW, UK
Pages 1327-1331 | Published online: 31 Aug 2006

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Peter Norman. (2012) Evaluation of WO-2012085582 and WO-2012085583 two identified MABAs: backups to AZD-2115?. Expert Opinion on Therapeutic Patents 22:11, pages 1377-1383.
Read now
Peter Norman. (2012) Novel dihydroquinoline-based MABAs; clues to the identity of LAS-190792: evaluation of WO20111411802. Expert Opinion on Therapeutic Patents 22:2, pages 185-192.
Read now
Nicholas C Ray & Lilian Alcaraz. (2009) Muscarinic antagonist-β-adrenergic agonist dual pharmacology molecules as bronchodilators: a patent review. Expert Opinion on Therapeutic Patents 19:1, pages 1-12.
Read now
Peter Norman. (2008) Pfizer's dual-acting β2 agonists/muscarinic M3 antagonists. Expert Opinion on Therapeutic Patents 18:9, pages 1091-1096.
Read now

Articles from other publishers (3)

A. Prakash, K.S. Babu & J.B. Morjaria. (2013) Novel anti-cholinergics in COPD. Drug Discovery Today 18:21-22, pages 1117-1126.
Crossref
Mario Cazzola, Luigino Calzetta & Maria Gabriella Matera. (2011) β2-adrenoceptor agonists: current and future direction. British Journal of Pharmacology 163:1, pages 4-17.
Crossref
Ilaria Peretto, Paola Petrillo & Bruno P. Imbimbo. (2009) Medicinal chemistry and therapeutic potential of muscarinic M3 antagonists. Medicinal Research Reviews 29:6, pages 867-902.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.